RU2016150535A - Новые соединения - Google Patents
Новые соединения Download PDFInfo
- Publication number
- RU2016150535A RU2016150535A RU2016150535A RU2016150535A RU2016150535A RU 2016150535 A RU2016150535 A RU 2016150535A RU 2016150535 A RU2016150535 A RU 2016150535A RU 2016150535 A RU2016150535 A RU 2016150535A RU 2016150535 A RU2016150535 A RU 2016150535A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- methylphenyl
- chloro
- methylpiperazin
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 29
- -1 monocyclic sulfone Chemical class 0.000 claims 17
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- VKCPQGYMMSAKAQ-INIZCTEOSA-N N-[5-chloro-3-[[(3S)-4-(2-cyclopropylacetyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-5-cyano-6-methylpyridine-3-carboxamide Chemical compound ClC=1C=C(C(=C(C1)NC(C1=CN=C(C(=C1)C#N)C)=O)C)CN1C[C@@H](N(CC1)C(CC1CC1)=O)C VKCPQGYMMSAKAQ-INIZCTEOSA-N 0.000 claims 5
- HGEZOHPCAWRILZ-HNNXBMFYSA-N N-[5-chloro-3-[[(3S)-4-(2-cyclopropylacetyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-5-fluoro-6-methylpyridine-3-carboxamide Chemical compound ClC=1C=C(C(=C(C1)NC(C1=CN=C(C(=C1)F)C)=O)C)CN1C[C@@H](N(CC1)C(CC1CC1)=O)C HGEZOHPCAWRILZ-HNNXBMFYSA-N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- QXPUCNBFKYBNCI-INIZCTEOSA-N N-[5-cyano-3-[[(3S)-4-(2-cyclopropylacetyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-5-fluoro-6-methylpyridine-3-carboxamide Chemical compound C(#N)C=1C=C(C(=C(C1)NC(C1=CN=C(C(=C1)F)C)=O)C)CN1C[C@@H](N(CC1)C(CC1CC1)=O)C QXPUCNBFKYBNCI-INIZCTEOSA-N 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- DSTQEIOPHFONIA-KRWDZBQOSA-N N-[5-chloro-3-[[(3S)-4-(2-cyclopropylacetyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-6-cyano-5-methylpyridine-3-carboxamide Chemical compound ClC=1C=C(C(=C(C1)NC(C1=CN=C(C(=C1)C)C#N)=O)C)CN1C[C@@H](N(CC1)C(CC1CC1)=O)C DSTQEIOPHFONIA-KRWDZBQOSA-N 0.000 claims 3
- QPXPWCFEYAVNKD-INIZCTEOSA-N N-[5-chloro-3-[[(3S)-4-(2-cyclopropylacetyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-6-cyanopyridine-3-carboxamide Chemical compound ClC=1C=C(C(=C(C1)NC(C1=CN=C(C=C1)C#N)=O)C)CN1C[C@@H](N(CC1)C(CC1CC1)=O)C QPXPWCFEYAVNKD-INIZCTEOSA-N 0.000 claims 3
- GRQJEVKIBDYWST-KRWDZBQOSA-N N-[5-chloro-3-[[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-2-cyanopyridine-4-carboxamide Chemical compound ClC=1C=C(C(=C(C1)NC(C1=CC(=NC=C1)C#N)=O)C)CN1C[C@@H](N(CC1)C(=O)C1CCCC1)C GRQJEVKIBDYWST-KRWDZBQOSA-N 0.000 claims 3
- DTZVGKPLTWOKMO-KRWDZBQOSA-N N-[5-chloro-3-[[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-6-cyanopyridine-3-carboxamide Chemical compound ClC=1C=C(C(=C(C1)NC(C1=CN=C(C=C1)C#N)=O)C)CN1C[C@@H](N(CC1)C(=O)C1CCCC1)C DTZVGKPLTWOKMO-KRWDZBQOSA-N 0.000 claims 3
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- HWRJLUDFSRAVFV-HNNXBMFYSA-N N-[5-chloro-3-[[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-4,4,4-trifluorobutanamide Chemical compound ClC=1C=C(C(=C(C=1)NC(CCC(F)(F)F)=O)C)CN1C[C@@H](N(CC1)C(=O)C1CCCC1)C HWRJLUDFSRAVFV-HNNXBMFYSA-N 0.000 claims 2
- NGKHAJANRHPUJR-KRWDZBQOSA-N N-[5-chloro-3-[[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-4-cyanobutanamide Chemical compound ClC=1C=C(C(=C(C1)NC(CCCC#N)=O)C)CN1C[C@@H](N(CC1)C(=O)C1CCCC1)C NGKHAJANRHPUJR-KRWDZBQOSA-N 0.000 claims 2
- FCRIJMWHPMMORC-KRWDZBQOSA-N N-[5-chloro-3-[[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-5-cyano-6-methylpyridine-3-carboxamide Chemical compound ClC=1C=C(C(=C(C1)NC(C1=CN=C(C(=C1)C#N)C)=O)C)CN1C[C@@H](N(CC1)C(=O)C1CCCC1)C FCRIJMWHPMMORC-KRWDZBQOSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 1
- PRLNKBJVTMKIGO-UHFFFAOYSA-N 1-(azetidin-1-yl)propan-1-one Chemical group CCC(=O)N1CCC1 PRLNKBJVTMKIGO-UHFFFAOYSA-N 0.000 claims 1
- QZQHEPUZEQZTTJ-INIZCTEOSA-N 5-N-[5-chloro-3-[[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]pyridine-2,5-dicarboxamide Chemical compound ClC=1C=C(C(=C(C=1)NC(=O)C=1C=CC(=NC=1)C(=O)N)C)CN1C[C@@H](N(CC1)C(=O)C1CCCC1)C QZQHEPUZEQZTTJ-INIZCTEOSA-N 0.000 claims 1
- SQZKZGLNOUAVHJ-AWEZNQCLSA-N 5-chloro-N-[3-[[(3S)-4-(2,2-difluorobutanoyl)-3-methylpiperazin-1-yl]methyl]-5-fluoro-2-methylphenyl]-6-methylpyridine-3-carboxamide Chemical compound ClC=1C(=NC=C(C(=O)NC2=C(C(=CC(=C2)F)CN2C[C@@H](N(CC2)C(C(CC)(F)F)=O)C)C)C=1)C SQZKZGLNOUAVHJ-AWEZNQCLSA-N 0.000 claims 1
- ZULKJUFZKBRHSB-HNNXBMFYSA-N 5-chloro-N-[3-[[(3S)-4-(2-cyclopropylacetyl)-3-methylpiperazin-1-yl]methyl]-5-fluoro-2-methylphenyl]-6-methylpyridine-3-carboxamide Chemical compound ClC=1C(=NC=C(C(=O)NC2=C(C(=CC(=C2)F)CN2C[C@@H](N(CC2)C(CC2CC2)=O)C)C)C1)C ZULKJUFZKBRHSB-HNNXBMFYSA-N 0.000 claims 1
- PQQSXRKARRBHAQ-HNNXBMFYSA-N 5-chloro-N-[5-chloro-3-[[(3S)-4-(2-cyclopropylacetyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-6-methylpyridine-3-carboxamide Chemical compound ClC=1C(=NC=C(C(=O)NC2=C(C(=CC(=C2)Cl)CN2C[C@@H](N(CC2)C(CC2CC2)=O)C)C)C1)C PQQSXRKARRBHAQ-HNNXBMFYSA-N 0.000 claims 1
- VIXHYTFENNJPFA-AWEZNQCLSA-N 5-chloro-N-[5-chloro-3-[[(3S)-4-(cyclopropanecarbonyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-6-methylpyridine-3-carboxamide Chemical compound ClC=1C(=NC=C(C(=O)NC2=C(C(=CC(=C2)Cl)CN2C[C@@H](N(CC2)C(=O)C2CC2)C)C)C1)C VIXHYTFENNJPFA-AWEZNQCLSA-N 0.000 claims 1
- ZYQGFSDMGQAULE-INIZCTEOSA-N 5-chloro-N-[5-cyano-3-[[(3S)-4-(2-cyclopropylacetyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-6-methylpyridine-3-carboxamide Chemical compound ClC=1C(=NC=C(C(=O)NC2=C(C(=CC(=C2)C#N)CN2C[C@@H](N(CC2)C(CC2CC2)=O)C)C)C1)C ZYQGFSDMGQAULE-INIZCTEOSA-N 0.000 claims 1
- ZBSJAIQLGXOESH-HNNXBMFYSA-N 5-chloro-N-[5-fluoro-2-methyl-3-[[(3S)-3-methyl-4-(2-methylpropanoyl)piperazin-1-yl]methyl]phenyl]-6-methylpyridine-3-carboxamide Chemical compound ClC=1C(=NC=C(C(=O)NC2=C(C(=CC(=C2)F)CN2C[C@@H](N(CC2)C(C(C)C)=O)C)C)C1)C ZBSJAIQLGXOESH-HNNXBMFYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 239000004214 Fast Green FCF Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- RTDYDXFJLKEJIZ-HNNXBMFYSA-N N-[3-[[(3S)-4-butanoyl-3-methylpiperazin-1-yl]methyl]-5-chloro-2-methylphenyl]-5-fluoro-6-methylpyridine-3-carboxamide Chemical compound C(CCC)(=O)N1[C@H](CN(CC1)CC=1C(=C(C=C(C1)Cl)NC(C1=CN=C(C(=C1)F)C)=O)C)C RTDYDXFJLKEJIZ-HNNXBMFYSA-N 0.000 claims 1
- OJDMEOSJDNLOGJ-HNNXBMFYSA-N N-[3-[[(3S)-4-butanoyl-3-methylpiperazin-1-yl]methyl]-5-fluoro-2-methylphenyl]-5-chloro-6-methylpyridine-3-carboxamide Chemical compound C(CCC)(=O)N1[C@H](CN(CC1)CC=1C(=C(C=C(C1)F)NC(C1=CN=C(C(=C1)Cl)C)=O)C)C OJDMEOSJDNLOGJ-HNNXBMFYSA-N 0.000 claims 1
- UDUDCWQNJWSRNE-AWEZNQCLSA-N N-[5-chloro-3-[[(3S)-4-(2,2-difluorobutanoyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-5-fluoro-6-methylpyridine-3-carboxamide Chemical compound ClC=1C=C(C(=C(C=1)NC(C1=CN=C(C(=C1)F)C)=O)C)CN1C[C@@H](N(CC1)C(C(CC)(F)F)=O)C UDUDCWQNJWSRNE-AWEZNQCLSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000004126 brilliant black BN Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000006006 difluoroethoxy group Chemical group 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000004174 erythrosine Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/000540 | 2014-05-28 | ||
| CN2014000540 | 2014-05-28 | ||
| PCT/CN2015/079753 WO2015180612A1 (en) | 2014-05-28 | 2015-05-26 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016150535A true RU2016150535A (ru) | 2018-07-03 |
| RU2016150535A3 RU2016150535A3 (OSRAM) | 2018-12-26 |
Family
ID=54698093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016150535A RU2016150535A (ru) | 2014-05-28 | 2015-05-26 | Новые соединения |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9902735B2 (OSRAM) |
| EP (1) | EP3148975B1 (OSRAM) |
| JP (1) | JP6759110B2 (OSRAM) |
| KR (1) | KR20170012389A (OSRAM) |
| CN (1) | CN106536489B (OSRAM) |
| AU (1) | AU2015267909B2 (OSRAM) |
| BR (1) | BR112016027732B1 (OSRAM) |
| CA (1) | CA2950211C (OSRAM) |
| ES (1) | ES2710487T3 (OSRAM) |
| MX (1) | MX378098B (OSRAM) |
| RU (1) | RU2016150535A (OSRAM) |
| WO (1) | WO2015180612A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2928885T3 (en) | 2012-12-06 | 2017-05-15 | Glaxo Group Ltd | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES |
| CN106660999A (zh) | 2014-05-28 | 2017-05-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 新化合物 |
| CN107001342B (zh) | 2014-05-28 | 2020-02-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 新化合物 |
| CA3031759A1 (en) * | 2016-06-23 | 2017-12-28 | Kessler Foundation Inc. | Testosterone replacement therapy in combination with neuromuscular stimulation |
| PT3484880T (pt) | 2016-07-13 | 2020-12-07 | Leo Pharma As | Moduladores heteroaromáticos do recetor órfão gama relacionado com retinóide |
| KR20190094187A (ko) | 2016-12-21 | 2019-08-12 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 축합 고리기 아자시클로부틸 트리아졸 유도체, 이의 제조 방법 및 의약에서의 이의 용도 |
| MX2019007360A (es) | 2016-12-28 | 2019-08-16 | Jiangsu Hengrui Medicine Co | Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina. |
| CN109134476B (zh) * | 2017-06-15 | 2021-03-19 | 复旦大学 | 桥环哌嗪类衍生物或其盐及其制备方法和用途 |
| WO2019022223A1 (ja) * | 2017-07-28 | 2019-01-31 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
| CN107698462A (zh) * | 2017-10-10 | 2018-02-16 | 重庆科脉生物化工有限公司 | 一种1‑氨基‑1‑环丙腈盐酸盐的制备方法 |
| CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
| CN115244740A (zh) * | 2020-03-06 | 2022-10-25 | 日产化学株式会社 | 新型催化剂组合物以及具有含氮基团的碳材料 |
| EP4161923A4 (en) * | 2020-06-09 | 2023-10-11 | Relive Therapeutics Inc. | Compounds comprising a three ring core as pd-1/pd-l1 blockers |
| CN116239445B (zh) * | 2023-01-05 | 2024-10-18 | 万华化学集团股份有限公司 | 一种丙内酯开环加氢合成1,3-丙二醇的方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0873320B1 (en) * | 1995-12-18 | 2002-06-12 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as tachykinin antagonists |
| US7790726B2 (en) * | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| EP1962852B1 (en) * | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2012027965A1 (en) * | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| EP2511263A1 (en) * | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| WO2012145254A2 (en) | 2011-04-16 | 2012-10-26 | Board Of Regents, The University Of Texas System | Methods of using inhibitors of rorϒt to treat disease |
| CN103619824B (zh) | 2011-04-28 | 2015-09-09 | 日本烟草产业株式会社 | 酰胺化合物及其药物用途 |
| WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| EP2753327A4 (en) | 2011-09-09 | 2015-04-08 | Univ New York | AMIDOVER BINDINGS AS RORYT MODULATORS AND ITS USE |
| GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
| PE20142400A1 (es) | 2012-04-27 | 2015-02-04 | Glaxo Group Ltd | Compuestos novedosos |
| GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
| DK2928885T3 (en) * | 2012-12-06 | 2017-05-15 | Glaxo Group Ltd | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| WO2015061686A2 (en) | 2013-10-25 | 2015-04-30 | St. Jude Children's Research Hospital, Inc. | Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer |
| CA2928537A1 (en) | 2013-10-25 | 2015-04-30 | Glaxosmithkline Llc | Novel compounds |
| CN106660999A (zh) | 2014-05-28 | 2017-05-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 新化合物 |
| CN107001342B (zh) | 2014-05-28 | 2020-02-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 新化合物 |
-
2015
- 2015-05-26 ES ES15800398T patent/ES2710487T3/es active Active
- 2015-05-26 BR BR112016027732-5A patent/BR112016027732B1/pt active IP Right Grant
- 2015-05-26 CN CN201580039564.9A patent/CN106536489B/zh active Active
- 2015-05-26 RU RU2016150535A patent/RU2016150535A/ru not_active Application Discontinuation
- 2015-05-26 MX MX2016015630A patent/MX378098B/es unknown
- 2015-05-26 US US15/314,111 patent/US9902735B2/en active Active
- 2015-05-26 EP EP15800398.8A patent/EP3148975B1/en active Active
- 2015-05-26 AU AU2015267909A patent/AU2015267909B2/en not_active Ceased
- 2015-05-26 JP JP2016569766A patent/JP6759110B2/ja active Active
- 2015-05-26 KR KR1020167036017A patent/KR20170012389A/ko not_active Withdrawn
- 2015-05-26 CA CA2950211A patent/CA2950211C/en active Active
- 2015-05-26 WO PCT/CN2015/079753 patent/WO2015180612A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2950211C (en) | 2023-02-07 |
| US9902735B2 (en) | 2018-02-27 |
| RU2016150535A3 (OSRAM) | 2018-12-26 |
| BR112016027732A2 (OSRAM) | 2017-08-15 |
| MX2016015630A (es) | 2017-04-25 |
| CN106536489B (zh) | 2020-02-07 |
| US20170197978A1 (en) | 2017-07-13 |
| JP2017516796A (ja) | 2017-06-22 |
| MX378098B (es) | 2025-03-10 |
| CN106536489A (zh) | 2017-03-22 |
| KR20170012389A (ko) | 2017-02-02 |
| WO2015180612A1 (en) | 2015-12-03 |
| CA2950211A1 (en) | 2015-12-03 |
| BR112016027732B1 (pt) | 2023-11-07 |
| EP3148975B1 (en) | 2018-11-28 |
| AU2015267909B2 (en) | 2018-03-22 |
| JP6759110B2 (ja) | 2020-09-23 |
| EP3148975A4 (en) | 2018-01-03 |
| AU2015267909A1 (en) | 2016-12-01 |
| ES2710487T3 (es) | 2019-04-25 |
| EP3148975A1 (en) | 2017-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016150535A (ru) | Новые соединения | |
| RU2486181C2 (ru) | Пиримидилциклопентаны как ингибиторы акт-протеинкиназ | |
| JP2017516796A5 (OSRAM) | ||
| RU2010134411A (ru) | Фенилацетамидное производное | |
| HRP20180335T1 (hr) | Kondenzirani derivati imidazola korisni kao ido inhibitori | |
| JP2010539110A5 (OSRAM) | ||
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| JP2019527718A5 (OSRAM) | ||
| CA2903288A1 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| RU2018106453A (ru) | Соединения | |
| JP2014523851A5 (OSRAM) | ||
| JP2017525757A5 (OSRAM) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| WO2014181287A1 (en) | Heterocyclyl compounds and uses thereof | |
| JP2009518340A5 (OSRAM) | ||
| JP2019502763A5 (OSRAM) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| JP2004502670A5 (OSRAM) | ||
| JP2017538689A5 (OSRAM) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2017509676A5 (OSRAM) | ||
| JP2017525737A5 (OSRAM) | ||
| RU2016104844A (ru) | Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора | |
| HRP20171763T1 (hr) | Derivati piridin-4-ila |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190712 |